UniQure Huntington's Drug Faces FDA Setback, Shares Drop 19%

UniQure stock tumbles as FDA says AMT-130 gene therapy data insufficient for approval. Company seeks urgent Q1 2026 meeting to advance Huntington's disease treatment.